Literature DB >> 10489937

Lack of evidence for fibrosing colonopathy by 5-ASA in humans.

M L Borum, A L Ginsberg.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1999        PMID： 10489937     DOI： 10.1023/a:1026676407838

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN： 0163-2116            Impact factor:   3.199


× No keyword cloud information.
  10 in total

1.  Fatal myocarditis associated with mesalazine.

Authors:  K S Kristensen; A Høegholm; L Bohr; S Friis
Journal:  Lancet       Date:  1990-03-10       Impact factor: 79.321

Review 2.  Hypersensitivity to 5-ASA suppositories.

Authors:  M L Borum; A Ginsberg
Journal:  Dig Dis Sci       Date:  1997-05       Impact factor: 3.199

3.  Peripheral neuropathy and mesalazine.

Authors:  D K Woodward
Journal:  BMJ       Date:  1989-11-11

4.  Acute pancreatitis due to 5-aminosalicylate.

Authors:  B Sachedina; F Saibil; L B Cohen; J Whittey
Journal:  Ann Intern Med       Date:  1989-03-15       Impact factor: 25.391

5.  Comparative and experimental pathology of fibrosing colonopathy.

Authors:  D van Velzen; L M Ball; A R Dezfulian; A Southgate; C V Howard
Journal:  Postgrad Med J       Date:  1996-03       Impact factor: 2.401

6.  High-dose pancreatic-enzyme supplements and fibrosing colonopathy in children with cystic fibrosis.

Authors:  S C FitzSimmons; G A Burkhart; D Borowitz; R J Grand; T Hammerstrom; P R Durie; J D Lloyd-Still; A B Lowenfels
Journal:  N Engl J Med       Date:  1997-05-01       Impact factor: 91.245

7.  Clinical experience of the tolerance of mesalazine and olsalazine in patients intolerant of sulphasalazine.

Authors:  S S Rao; P A Cann; C D Holdsworth
Journal:  Scand J Gastroenterol       Date:  1987-04       Impact factor: 2.423

8.  Hypersensitivity reaction to sulfasalazine with severe hepatotoxicity.

Authors:  R P Sotolongo; L I Neefe; C Rudzki; K G Ishak
Journal:  Gastroenterology       Date:  1978-07       Impact factor: 22.682

Review 9.  New oral salicylates in the therapy of chronic idiopathic inflammatory bowel disease.

Authors:  M G Robinson
Journal:  Gastroenterol Clin North Am       Date:  1989-03       Impact factor: 3.806

10.  Hypersensitivity with hepatotoxicity to mesalazine after hypersensitivity to sulfasalazine.

Authors:  M L Hautekeete; N Bourgeois; P Potvin; L Duville; H Reynaert; G Devis; M Adler; G Klöppel
Journal:  Gastroenterology       Date:  1992-12       Impact factor: 22.682
  10 in total
  1 in total

1.  Lack of evidence for fibrosing colonopathy by 5-ASA in humans.

Authors:  Marie T Bakowski; Philip Prescott
Journal:  Dig Dis Sci       Date:  2002-02       Impact factor: 3.199
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.